Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0FPNZF
ADC Name	1F6-Met- (D)Lys-AF
Drug Status	Investigative
Indication	In total 2 Indication(s) Hodgkin lymphoma [ICD11:2B30] Investigative Renal cell carcinoma [ICD11:2C90] Investigative
Structure
	3D MOL	2D MOL
Antibody Name	Anti-CD70 mAb IF6		Antibody Info
Antigen Name	CD70 antigen (CD70)		Antigen Info
Payload Name	Auristatin F		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mal-Met-D-Lys		Linker Info

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	86.68	%	DBTRG-05MG cells	Anaplastic astrocytoma
Tumor Growth Inhibition value (TGI)	92.4	%	786-O cells	Renal cell carcinoma

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	9	ng/mL	Caki-1 cells	Clear cell renal cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	12	ng/mL	786-O cells	Renal cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	168	ng/mL	L-428 cells	Hodgkin lymphoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	86.68% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.40% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	168.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

References

Ref 1	Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate.